Bottom line
Is NVU a good fund? The bottom line
NVU is a managed leveraged & inverse ETF from Graniteshares.
It charges 1.39% — about $139 a year on every $10,000 invested, more expensive than 64% of leveraged & inverse funds we track.
Updated Nov 19, 2026
What NVU invests in
The Fund seeks daily investment results, before fees and expenses, of 2 times (200%) the daily percentage change of the ADR of Novo Nordisk A/S (NYSE: NVO).
The Fund is an actively managed exchange-traded fund that attempts to replicate 2 times (200%) the daily percentage change of the Underlying Stock by entering into financial instruments such as swaps and options on the Underlying Stock as well as directly purchasing the Underlying Stock. At the end of each trading day, the notional exposure against the Underlying Stock obtained through the combination of these instruments will be approximately 200% of the Funds net asset value. The Fund aims to generate the inverse daily performance of the Underlying Stock for a single day. A single day is defined as being calculated from the close of regular trading on one trading day to the close on the next trading day. The Fund will aim to primarily obtain its notional exposure against the Underlying Stock through swap agreements. In case the Fund faces restriction in increasing its swap notional…
From the fund's prospectus (filed Oct 28, 2026).
What NVU costs
On a $10,000 investment, NVU's 1.39% expense ratio costs about $139 a year. The median leveraged & inverse fund charges 1.31%.